Hit-to-lead optimization on aryloxybenzamide derivative virtual screening hit against SIRT
作者:Semih Yagci、Mahmut Gozelle、Selen Gozde Kaya、Yesim Ozkan、Ahmet Bugra Aksel、Filiz Bakar-Ates、Yasemin Dundar、Gokcen Eren
DOI:10.1016/j.bmc.2020.115961
日期:2021.1
performed a pharmacophore-based virtual screening campaign and an aryloxybenzamide derivative (1) displaying SIRT1/2 inhibitory effect was identified as a hit compound. In the current study, the hit-to-lead optimization on the hit compound was explored in order to improve the SIRT binding and inhibition. Fourteen compounds, ten of which were new, have been synthesized and subjected to in vitro biological
Sirtuins (SIRTs) 是一类烟酰胺腺嘌呤二核苷酸 (NAD + ) 依赖性蛋白组蛋白脱乙酰酶 (HDAC),从细菌到哺乳动物都进化保守。这组酶使用 NAD +作为共底物催化组蛋白或非组蛋白底物中赖氨酸残基的可逆脱乙酰化。大量研究表明,SIRT 的异常酶活性与糖尿病、癌症和神经退行性疾病等多种疾病有关。之前,我们进行了基于药效团的虚拟筛选活动和芳氧基苯甲酰胺衍生物 ( 1) 显示 SIRT1/2 抑制作用被确定为命中化合物。在当前的研究中,探索了对命中化合物的hit-to-lead优化以改善SIRT结合和抑制。已经合成了 14 种化合物,其中 10 种是新化合物,并对其对 SIRT1-3 的抑制活性进行了体外生物学评估。通过进行结构修饰,与命中化合物相比,观察到ST01、ST02和ST11 的选择性 SIRT1 抑制显着改善。对于ST14观察到最高的 SIRT2 抑制活性,这是根据与为